Form 4: Verve Therapeutics Executive Andrew Ashe Reports Stock Transactions

Andrew Ashe, President, COO, and General Counsel of Verve Therapeutics, reports the settlement of restricted stock units and a sale of shares to cover withholding tax liability.

Summary

• On April 1, 2025, Andrew Ashe settled 9,000 restricted stock units (RSUs) into common stock.
• On April 2, 2025, Ashe sold 2,681 shares of common stock at a price of $4.15 per share.
• The sale was executed under a pre-arranged automatic sale plan to cover withholding tax obligations related to the vesting of RSUs.
• Following these transactions, Ashe directly owns 348,828 shares of Verve Therapeutics common stock and 27,000 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive, which is a routine occurrence. There is no indication of positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency into the trading activities of key personnel and their holdings in the company.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The transactions are similar to those of executives at comparable biotech firms such as CRISPR Therapeutics and Editas Medicine, where stock grants and sales are part of compensation packages.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold by the executive.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Verve Therapeutics, Andrew Ashe, stock, RSU, restricted stock units, Form 4, insider trading, securities, beneficial ownership, automatic sale plan